Butadionum

General characteristics. Structure:

Active ingredient: phenylbutazone of 1 g in each tuba.

Excipients: methylparahydroxybenzoate, carboxymethylcellulose of sodium, silicon dioxide colloid, polysorbate 60, глицерол (85%), propylene glycol, liquid paraffin, the water purified.

Pharmacological properties:

Pharmacodynamics. Nonsteroid antiinflammatory drug, possesses antiinflammatory and soothing action. Not selectively inhibits activity of cyclooxygenase (TsOG-1 and TsOG-2) and slows down synthesis of prostaglandins.
Phenylbutazone inhibits synthesis of ATP-dependent mucopolysaccharides.
Butadionum is used for elimination of a pain syndrome and reduction of the puffiness connected with inflammatory process. At topical administration causes easing or disappearance of joint pains at rest and at the movement. Reduces morning constraint and a swelling of joints, promotes increase in volume of movements.

Pharmacokinetics. At application system absorption makes no more than 5%.
Phenylbutazone is exposed to metabolism in a liver, is emitted in the form of metabolites generally with kidneys and about 1/4 through intestines. Elimination time from a blood plasma long (on average 70 h, at elderly people to 105 h).

Indications to use:

Posttraumatic inflammation of soft tissues and joints, for example, as a result of stretchings, retension and bruises.
Rheumatic diseases of soft tissues (tendovaginitis, bursitis, defeat of periartikulyarny fabrics). Muscular pains of a rheumatic and not rheumatic origin.
The pain syndrome and puffiness connected with diseases of muscles and joints.
Pseudorheumatism, osteoarthrosis, radiculitis, lumbago, sciatica.

Route of administration and doses:

Outwardly.
Adults and children are more senior than 14 years: drug is applied with a thin layer, a strip of 2-3 cm over the inflammation center without rubbing in by 2-3 times a day. Course of treatment of 7-10 days. After 10 days of use it is necessary to consult with the doctor.
Elderly patients: there is no need for the special mode of use.

Features of use:

At emergence of erubescence therapy should be stopped.
Ointment should be applied only on the unimpaired skin, avoiding hit on open wounds. After drawing it is not necessary to apply an occlusive bandage.
It is not necessary to allow hits of drug in eyes and on mucous membranes.
Drug should not be used for treatment of thrombophlebitis of deep veins of extremities. For the prevention of a photosensitization it is necessary to protect skin from hit of direct sunshine. When sharing from an inma dosage forms of Butadionum it is necessary to consider the maximum daily dose of this medicine.

Side effects:

Local reactions: eczema, a photosensitization, contact dermatitis (an itch, reddening, puffiness of the processed site of skin; papules, vesicles, peeling).
Allergic reactions: small tortoiseshell, Quincke's disease, bronchospasm, generalized skin rash.

Interaction with other medicines:

Clinically significant interaction with other medicines is not described.
It is necessary to avoid combined use of Butadionum with other non-steroidal anti-inflammatory drugs.
Drug can strengthen effect of the drugs causing a photosensitization.

Contraindications:

Hypersensitivity to phenylbutazone or other components of drug, to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NPVP); anamnestic data on an attack of a bronkhoobstruktion, allergic rhinitis, small tortoiseshell after reception of acetylsalicylic acid or other NPVP; pregnancy (I and III trimester), lactation period; disturbance of integrity of integuments in the place of alleged drawing; children's age up to 14 years; combined use with other drugs containing phenylbutazone.

Pregnancy and lactation
Drug is contraindicated in I and III trimesters of pregnancy because of a possibility of disturbances of fetation. In the II trimester of pregnancy Butadionum is applied only if the estimated advantage for mother exceeds potential risk for a fruit. In need of use of drug in the period of a lactation breastfeeding is recommended to be stopped.

Overdose:

Extremely low absorption of active components of drug at external use makes overdose almost impossible.
At an accidental proglatyvaniye of large amounts of ointment (more than 20 g) emergence of the system undesirable reactions characteristic of NPVP is possible. The gastric lavage, reception of absorbent carbon is necessary.

Storage conditions:

To store at a temperature from 8 to 15 °C. To store in the place, unavailable to children!

Issue conditions:

Without recipe

Packaging:

Ointment for external use of 5% 20 g of ointment in an aluminum tuba with white polyethylene the cap having the perforating tip. One tuba in a cardboard pack with the instruction on a medical use.